Next-Generation Genomic Sequencing: Market Evaluation

A Panel Discussion Among Genomic Sequencing Experts

September 2007

Deliverable: Transcript with key findings

Study Description and Objectives

§    From current Illumina/Solexa users, determine:

·     Drivers of initial adoption

·     Current utilization and applications

·     Levels of satisfaction with the product/technology

·     Strengths and weaknesses of the product

·     Appetite for additional purchases

§    From those (e.g., core labs and smaller academic centers) evaluating the Illumina/Solexa product and others, determine:

·     Existing platforms now in use

·     Barriers to adoption

·     Specific competing products under consideration

·     Purchasing criteria

·     Purchasing timelines

§    From all participants, explore the attributes, merits, and demerits of competing products, including:

·     Applied Biosystems SOLiD system (now in market via “early access program”)

·     454 Life Sciences sequencer (marketed by Roche Diagnostics)

·     Helicos Biosciences tSMS platform

§    Explore specific additional issues, including:

·     Thoughts on the potential for de novo sequencing using Illumina/Solexa, others

·     Time horizon for single-molecule sequencing, and who will get there first

·     Potential for longer read lengths being accommodated by any of the competitors

·     The future of capillary sequencing

·     Other competing technologies not previously discussed

Companies and Products Mentioned in This Report

Inclusion Criteria and Panelist Demographics

Represented Institutions

To purchase this report or request additional information, contact:

Print Abstract

For additional information on this study or to purchase, please call: